International Journal of Clinical Oncology

期刊名
International Journal of Clinical Oncology

INT J CLIN ONCOL

ISSN / eISSN
1341-9625 / 1437-7772
目标和范围
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
研究方向

肿瘤学

CiteScore
6.00 查看趋势图
CiteScore 学科排名
类别 分区 排名
Medicine - Surgery Q1 #36/495
Medicine - Hematology Q2 #36/129
Medicine - Oncology Q2 #126/366
Web of Science 核心合集
Science Citation Index Expanded (SCIE) Social Sciences Citation Index (SSCI)
Indexed -
类别 (Journal Citation Reports 2023) 分区
ONCOLOGY - SCIE Q3
H-index
53
出版国家或地区
JAPAN
出版商
Springer Singapore
出版周期
Bimonthly
出版年份
1996
年文章数
185
Open Access
NO
通讯方式
SPRINGER TOKYO, 1-11-11 KUDAN-KITA, CHIYODA-KU, TOKYO, JAPAN, 102-0073
认证评论
注: 认证评论选取于全球各个学术评论平台和社交媒体。
I have been warned, and I feel that there is not much productivity in the editorial department. The submission speed is particularly slow, so I do not recommend submitting.
2023-03-27
The translation of the given text into English is: "The speed is quite fast, no opinions given, the content is not suitable and instantly rejected."
2022-07-01

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started